[go: up one dir, main page]

WO2003018617A1 - Method of purifying human mannose binding lectin, human mannose binding lectin compositions and medicinal use of human mannose binding lectin - Google Patents

Method of purifying human mannose binding lectin, human mannose binding lectin compositions and medicinal use of human mannose binding lectin Download PDF

Info

Publication number
WO2003018617A1
WO2003018617A1 PCT/JP2002/008790 JP0208790W WO03018617A1 WO 2003018617 A1 WO2003018617 A1 WO 2003018617A1 JP 0208790 W JP0208790 W JP 0208790W WO 03018617 A1 WO03018617 A1 WO 03018617A1
Authority
WO
WIPO (PCT)
Prior art keywords
mbl
binding lectin
mannose binding
human mannose
purifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008790
Other languages
French (fr)
Japanese (ja)
Inventor
Motonori Hashimoto
Naomi Asahara
Lyang-Ja Lee
Katsuki Ohtani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuso Pharmaceutical Industries Ltd
Mitsubishi Tanabe Pharma Corp
Original Assignee
Fuso Pharmaceutical Industries Ltd
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuso Pharmaceutical Industries Ltd, Mitsubishi Pharma Corp filed Critical Fuso Pharmaceutical Industries Ltd
Priority to JP2003523276A priority Critical patent/JP4051030B2/en
Publication of WO2003018617A1 publication Critical patent/WO2003018617A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It is intended to provide a method of purifying MBL from a human plasma material at a high yield and a high purity; a method of producing at a high yield a composition containing highly pure MBL from a human plasma material; compositions containing highly pure MBL holding the high-dimension homooligomer structure produced by the above method; and novel use of MBL. A human plasma material is brought into contact with polyethylene glycol to give a clear MBL solution which is useful as a material for purifying MBL or as a material for producing MBL. Then the solution is subjected to affinity chromatography and heparin chromatography. MBL is useful in preventing or treating infections caused by cytomegalovirus and hepatitis B virus.
PCT/JP2002/008790 2001-08-31 2002-08-30 Method of purifying human mannose binding lectin, human mannose binding lectin compositions and medicinal use of human mannose binding lectin Ceased WO2003018617A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003523276A JP4051030B2 (en) 2001-08-31 2002-08-30 Human mannose-binding lectin purification method, human mannose-binding lectin composition, and pharmaceutical use of human mannose-binding lectin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-264915 2001-08-31
JP2001264915 2001-08-31

Publications (1)

Publication Number Publication Date
WO2003018617A1 true WO2003018617A1 (en) 2003-03-06

Family

ID=19091446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008790 Ceased WO2003018617A1 (en) 2001-08-31 2002-08-30 Method of purifying human mannose binding lectin, human mannose binding lectin compositions and medicinal use of human mannose binding lectin

Country Status (2)

Country Link
JP (1) JP4051030B2 (en)
WO (1) WO2003018617A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089394A3 (en) * 2003-04-09 2005-08-25 Natimmune As Treatment of severe acute respiratory syndrome (sars)
WO2006046786A1 (en) * 2004-10-28 2006-05-04 Dobeel Co., Ltd. Method for the mass production of multimeric mannose binding lectin
JP2019214555A (en) * 2018-06-06 2019-12-19 株式会社ＭａｎａＨＳ Composition for prevention of virus infection
WO2021005500A1 (en) 2019-07-09 2021-01-14 Unichem Laboratories Ltd Stable formulations of recombinant proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064453A1 (en) * 1998-06-10 1999-12-16 Statens Serum Institut Purification process for production of mannan-binding lectin and an mbl medicinal product
WO2000070043A1 (en) * 1999-05-14 2000-11-23 Steffen Thiel Recombinant human mannan-binding lectin
WO2002041913A1 (en) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectins as adjuvants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064453A1 (en) * 1998-06-10 1999-12-16 Statens Serum Institut Purification process for production of mannan-binding lectin and an mbl medicinal product
WO2000070043A1 (en) * 1999-05-14 2000-11-23 Steffen Thiel Recombinant human mannan-binding lectin
WO2002041913A1 (en) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectins as adjuvants

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HOHLER T. ET AL.: "No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients", EXP. CLIN. IMMUNOGENET., vol. 15, no. 3, 1998, pages 130 - 133, XP002959868 *
HOLMSKOV U. ET AL.: "Purification and characterization of bovine mannan-binding protein", GLYCOBIOLOGY, vol. 3, no. 2, 1993, pages 147 - 153, XP002959867 *
SPILLER O.B. ET AL.: "Antibody-independent activation of the classical complement pathway by cytomegalovirus-infected fibroblasts", J. INFECT. DIS., vol. 178, no. 6, 1998, pages 1597 - 1603, XP002959869 *
STORGAARD P. ET AL.: "Isolation and characterization of porcine mannan-binding proteins of different size and ultrastructure", SCAND. J. IMMUNOL., vol. 43, no. 3, 1996, pages 289 - 296, XP000911949 *
TAN S.M. ET AL.: "Improvements on the purification of mannan-binding lectin and demonstration of its Ca2+-independent association with a C1s-like serine protease", BIOCHEM. J., vol. 319, no. 2, 1996, pages 329 - 332, XP000911833 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089394A3 (en) * 2003-04-09 2005-08-25 Natimmune As Treatment of severe acute respiratory syndrome (sars)
JP2006522751A (en) * 2003-04-09 2006-10-05 ナットイムネ・アクティーゼルスカブ Treatment of severe acute respiratory syndrome (SARS)
WO2006046786A1 (en) * 2004-10-28 2006-05-04 Dobeel Co., Ltd. Method for the mass production of multimeric mannose binding lectin
JP2019214555A (en) * 2018-06-06 2019-12-19 株式会社ＭａｎａＨＳ Composition for prevention of virus infection
JP7084627B2 (en) 2018-06-06 2022-06-15 株式会社マナＨｓコーポレーション Composition for preventing viral infections
WO2021005500A1 (en) 2019-07-09 2021-01-14 Unichem Laboratories Ltd Stable formulations of recombinant proteins

Also Published As

Publication number Publication date
JPWO2003018617A1 (en) 2004-12-09
JP4051030B2 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
HUP0400998A3 (en) Novel compounds of anti-inflammatory, immunomodulatory and anti-proliferatory effect, process for their preparation and pharmaceutical compositions containing them
WO2005019256A3 (en) Muteins of tear lipocalin
WO2001058412A3 (en) Extracts from residues left in the production of wine
WO2003041649A3 (en) Cyanoalkylamino derivatives as protease inhibitors
WO2004043339A3 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
WO2001044272A3 (en) Daptomycin analogs as antibacterial agents
NO20022285L (en) New <alfa> amino acid compounds, process of their preparation and pharmaceutical compositions containing them
AU2002310321A1 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
WO2002096457A3 (en) Stable liquid formulations of antibodies
MXPA04000756A (en) Novel compounds.
HUP0303358A3 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
WO2003059934A3 (en) Albumin fusion proteins
HUP0401434A3 (en) Photosensitizing agent containing sulphonated meso-tetra-phenylporphyrin, process for its preparation and pharmaceutical compositions containing thereof
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
DK1511761T3 (en) Process for producing cyclic peptides
HUP0103063A3 (en) Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them
GB0216001D0 (en) Process and composition
WO2004106322A3 (en) Polymorphs of aripiprazole
EE200300234A (en) Use of biphenylcarboxamide compounds as lipid-lowering agents, process for their preparation and pharmaceutical composition containing them
WO2001098245A3 (en) Triphenyl compounds as interleukin-4 antagonists
FI20012605A0 (en) Method for recovering sugars
EP1645279A4 (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
NO20010522L (en) New piperidine-4-sulfonamide compounds, process of their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003523276

Country of ref document: JP

122 Ep: pct application non-entry in european phase